Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jul;35(7):904-8.
doi: 10.1016/j.leukres.2010.10.007. Epub 2010 Nov 9.

Pattern of hypomethylating agents use among elderly patients with myelodysplastic syndromes

Rong Wang  1 , Cary P Gross, Ronald J Maggiore, Stephanie Halene, Pamela R Soulos, Azra Raza, Naomi Galili, Xiaomei Ma
Affiliations

Pattern of hypomethylating agents use among elderly patients with myelodysplastic syndromes

Rong Wang et al. Leuk Res. 2011 Jul.

Abstract

Little is known about how hypomethylating agents (HMAs) have been adopted into the treatment of myelodysplastic syndromes (MDS). We conducted a population-based study to assess the use of HMAs among 4416 MDS patients (age≥66 years) who were diagnosed during 2001-2005 and followed up through the end of 2007. Multivariate logistic regression models were utilized to evaluate the role of various patient characteristics. 475 (10.8%) patients had received HMAs by 2007, with the proportion increasing over time. Patients who were white (odds ratio (OR)=0.66, 95% confidence interval (CI): 0.46-0.95), male (OR=1.47, 95% CI: 1.19-1.82), young (Ptrend<0.01), more recently diagnosed (OR=1.90, 95% CI: 1.54-2.34), had fewer comorbidities (Ptrend<0.01), or had a history of other cancer (OR=1.28, 95% CI: 1.00-1.63) were more likely to receive HMAs. Compared with patients with refractory anemia, those diagnosed with refractory anemia with excess blasts or refractory cytopenia with multilineage dysplasia had a higher chance to be treated with HMAs (OR=3.52 and 2.32, respectively). Relatively few MDS patients were treated with HMAs during the introduction period of these agents, and multiple patient characteristics such as sex, comorbidities, and MDS subtype influence the likelihood a patient receives HMAs.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None of the authors have a conflict of interest to declare.

Figures

Figure 1
Figure 1
The Use of Hypomethylating Agents over Time
Figure 2
Figure 2
The Use of Hypomethylating Agents over Time, by Sex
Figure 3
Figure 3
The Use of Hypomethylating Agents over Time, by Elixhauser Comorbidity Score
Figure 4
Figure 4
The Use of Hypomethylating Agents over Time, by Elixhauser Comorbidity Score RA:Refractory anemia, RARS: refractory anemia with ring sideroblasts, RCMD: refractory cytopenia with multilineage dysplasia, RAEB: refractory anemia with excess blasts
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–2088. - PubMed
    1. Ma X, Does M, Raza A, Mayne ST. Myelodysplastic syndromes: incidence and survival in the United States. Cancer. 2007;109:1536–1542. - PubMed
    1. Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001–2004, using data from the NAACCR and SEER programs. Blood. 2008;112:45–52. - PubMed
    1. Sierra J, Perez WS, Rozman C, et al. Bone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia. Blood. 2002;100:1997–2004. - PubMed
    1. Hellstrom-Lindberg E, Malcovati L. Supportive care and use of hematopoietic growth factors in myelodysplastic syndromes. Semin Hematol. 2008;45:14–22. - PubMed

Publication types